Under construction – not a live service

Skip to content

Frontlight Research

Institution

Massachusetts General Hospital

Boston, United StatesWebsite

Also known as: Hospital General de Massachusetts · Mass General · MGH

851running trials
414closed trials
6researchers
259,146publications (OpenAlex)

Researchers

Running trials

Not yet recruiting
Adiposity Distribution in Acute Respiratory Failure
NCT07019987· Maurizio F. Cereda, MD· Source
Not yet recruiting
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
NCT07216859· Kaiser Permanente· Source
Not yet recruiting
Intervention to Reduce Implicit Bias in Pharmacies
NCT06487351· Massachusetts General Hospital· Source
Not yet recruiting
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
NCT06957821· Early phase 1· Massachusetts General Hospital· Source
Not yet recruiting
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
NCT07226830· BioSensics· Source
Not yet recruiting
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT07923526· Phase 2/3· United Therapeutics· Source
Not yet recruiting
Safety Study of XT-150 in Participants With ALS
NCT06704347· Phase 1· Xalud Therapeutics, Inc.· Source
Not yet recruiting
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
NCT07892664· Phase 2/3· Massachusetts General Hospital· Source
Not yet recruiting
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
NCT07265739· Phase 2· Massachusetts General Hospital· Source
Not yet recruiting
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
NCT07240805· BioSensics· Source
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
NCT07765836· Phase 2· Massachusetts General Hospital· Source
Not yet recruiting
Training on Systemic and Organ Spec. PM in PC
NCT07768917· Massachusetts General Hospital· Source
Not yet recruiting
Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization
NCT07569250· University of Colorado, Denver· Source
Not yet recruiting
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
NCT07926321· Phase 2· Boehringer Ingelheim· Source
Recruiting
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
NCT06791057· Massachusetts General Hospital· Source
Not yet recruiting
Feasibility and Acceptability of Amani
NCT07648043· Phase 1/2· Massachusetts General Hospital· Source
Not yet recruiting
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
NCT07729332· Phase 4· Massachusetts General Hospital· Source
Not yet recruiting
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
NCT07569367· BioSensics· Source
Recruiting
Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)
NCT07665372· Johns Hopkins University· Source
Not yet recruiting
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT07923591· Phase 2· United Therapeutics· Source
Not yet recruiting
Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation
NCT07904351· Massachusetts General Hospital· Source
Not yet recruiting
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A
NCT07685028· Massachusetts General Hospital· Source
Not yet recruiting
taVNS Treatment for Fibromyalgia
NCT04777500· Massachusetts General Hospital· Source
Not yet recruiting
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907· P+F Products + Features USA Inc.· Source
Not yet recruiting
Inhaled Nitric Oxide in Severe Obesity
NCT06675435· Massachusetts General Hospital· Source
Not yet recruiting
The Care for America's Aging Study
NCT06021704· Massachusetts General Hospital· Source
Not yet recruiting
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
NCT07755059· Massachusetts General Hospital· Source
Not yet recruiting
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
NCT07520110· Phase 3· University of Massachusetts, Worcester· Source
Enrolling by invitation
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
NCT07688239· Phase 2· Tiziana Life Sciences LTD· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Not yet recruiting
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
NCT07077083· Phase 2· Massachusetts General Hospital· Source
Recruiting
MDMA-assisted Therapy for Fibromyalgia
NCT06066853· Early phase 1· Spaulding Rehabilitation Hospital· Source
Recruiting
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression
NCT07699445· Phase 4· Massachusetts General Hospital· Source
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
NCT07444476· Phase 3· Biogen· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
NCT07355335· Phase 1· Massachusetts General Hospital· Source
Not yet recruiting
Developing Resiliency and Exercise Using AI-based Messaging
NCT07225283· Massachusetts General Hospital· Source
Not yet recruiting
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
NCT04753320· Massachusetts General Hospital· Source
Recruiting
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215· Phase 2· Bayer· Source
Recruiting
Time Restricted Eating (TRE) in Bipolar Disorder
NCT07211217· Massachusetts General Hospital· Source
Not yet recruiting
Ready for Recovery Pilot Trial
NCT07797504· Massachusetts General Hospital· Source
Recruiting
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
NCT07010302· Phase 4· Massachusetts General Hospital· Source
Recruiting
Healey ALS MyMatch Common Screening Protocol
NCT07400393· Massachusetts General Hospital· Source
Recruiting
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926· Phase 4· Blue Earth Diagnostics· Source
Not yet recruiting
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
NCT07278492· Phase 1· Brigham and Women's Hospital· Source
Recruiting
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
NCT06996652· Phase 2· Yale University· Source
Recruiting
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
NCT07454733· Trustees of Dartmouth College· Source
Not yet recruiting
Medically Tailored Meals to Reduce Ultra-processed Food Intake in Colorectal Cancer Survivors
NCT07701707· Massachusetts General Hospital· Source
Not yet recruiting
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT07247097· Phase 2· Massachusetts General Hospital· Source

Showing 50 of 851.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer57 recruiting
Colorectal cancer35 recruiting
Ovarian cancer24 recruiting
Childhood cancers22 recruiting
Pancreatic cancer22 recruiting
Heart failure20 recruiting
Prostate cancer20 recruiting
Stroke19 recruiting
ALS (motor neurone disease)16 recruiting
Coronary artery disease16 recruiting
Gastric and oesophageal cancer16 recruiting
Melanoma16 recruiting
Head and neck cancer15 recruiting
Obesity15 recruiting
Alzheimer disease13 recruiting
Endometrial cancer13 recruiting
High blood pressure13 recruiting
Liver and biliary tract cancer13 recruiting
Metastatic breast cancer13 recruiting
Type 2 diabetes13 recruiting
Parkinson disease12 recruiting
Depression11 recruiting
Glioblastoma11 recruiting
Multiple myeloma11 recruiting
Triple-negative breast cancer11 recruiting
Acute myeloid leukaemia9 recruiting
Aortic stenosis9 recruiting
Atrial fibrillation9 recruiting
HIV9 recruiting
Bladder cancer8 recruiting
Cervical cancer8 recruiting
Cystic fibrosis8 recruiting
Aortic aneurysm7 recruiting
Chronic kidney disease7 recruiting
Myeloproliferative neoplasms7 recruiting
Peripheral artery disease7 recruiting
Pulmonary arterial hypertension7 recruiting
Sarcoma7 recruiting
Amyloidosis6 recruiting
Crohn's disease6 recruiting
Epilepsy6 recruiting
Idiopathic pulmonary fibrosis6 recruiting
Liver cirrhosis6 recruiting
Diffuse large B-cell lymphoma5 recruiting
Fibromyalgia5 recruiting
Mesothelioma5 recruiting
Myasthenia gravis5 recruiting
Myelodysplastic syndromes5 recruiting
Thyroid cancer5 recruiting
Ulcerative colitis5 recruiting
Follicular lymphoma4 recruiting
Immune thrombocytopenia (ITP)4 recruiting
Kidney cancer4 recruiting
Multiple sclerosis4 recruiting
Multiple system atrophy4 recruiting
Neuromyelitis optica (NMOSD)4 recruiting
Rheumatoid arthritis4 recruiting
Barrett's oesophagus3 recruiting
Bipolar disorder3 recruiting
Chronic lymphocytic leukaemia3 recruiting
Chronic myeloid leukaemia3 recruiting
COPD3 recruiting
Insomnia3 recruiting
Lewy body dementia3 recruiting
Lupus (SLE)3 recruiting
Meningioma3 recruiting
Neuroendocrine tumours3 recruiting
Osteoarthritis3 recruiting
Schizophrenia3 recruiting
Spinal cord injury3 recruiting
Type 1 diabetes3 recruiting
Acute lymphoblastic leukaemia2 recruiting
Asthma2 recruiting
Autism2 recruiting
Brain aneurysm2 recruiting
Coeliac disease2 recruiting
Cytomegalovirus infection2 recruiting
Down syndrome2 recruiting
Dystonia2 recruiting
Essential tremor2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
Frontotemporal dementia2 recruiting
Gastroparesis2 recruiting
Gout2 recruiting
Hearing loss2 recruiting
Huntington's disease2 recruiting
Mantle cell lymphoma2 recruiting
Sickle cell disease2 recruiting
Systemic sclerosis (scleroderma)2 recruiting
Vascular dementia2 recruiting
Alopecia areata1 recruiting
ANCA-associated vasculitis1 recruiting
Aplastic anaemia1 recruiting
Atopic dermatitis (eczema)1 recruiting
Bronchiectasis1 recruiting
Congenital heart disease1 recruiting
Duchenne muscular dystrophy1 recruiting
Hepatitis B1 recruiting
Hidradenitis suppurativa1 recruiting
Hodgkin lymphoma1 recruiting
Hypertrophic cardiomyopathy1 recruiting
Irritable bowel syndrome1 recruiting
Long COVID and ME/CFS1 recruiting
Myocarditis1 recruiting
Osteoporosis1 recruiting
Polycystic ovary syndrome1 recruiting
Primary biliary cholangitis1 recruiting
Retinitis pigmentosa1 recruiting
Spinal muscular atrophy1 recruiting
Thalassaemia1 recruiting
Vitiligo1 recruiting

Closed trials

Withdrawn
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
NCT05974293· Phase 2· Michael, Levy M.D.,Ph.D.· Source
Completed
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
NCT07417163· Massachusetts General Hospital· Source
Completed
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
NCT07420751· Massachusetts General Hospital· Source
Withdrawn
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
NCT07283848· Phase 2· Massachusetts General Hospital· Source
Completed
Pilot Study of a Brain Health Program in Senior Centers
NCT07424443· Massachusetts General Hospital· Source
Completed
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
NCT07364825· Brigham and Women's Hospital· Source
Withdrawn
Feasibility Study of LUM Imaging System for Pancreatic Cancer
NCT04276909· Lumicell, Inc.· Source
Completed
Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2
NCT06182241· Boston University Charles River Campus· Source
Completed
Prehabilitation for Aortic Aneurysm Surgery: Proof-of-concept Trial
NCT06998498· Massachusetts General Hospital· Source
Terminated
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344· Phase 2· Tisento Therapeutics· Source
Recruiting
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928· Phase 1· Mabwell (Shanghai) Bioscience Co., Ltd.· Source
Completed
Data Collection for Echocardiography-Based Software Assessment
NCT07126600· Anumana, Inc.· Source
Completed
Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT06853990· Deka Research and Development· Source
Terminated
Study of the Oral Treatment MTR-601 in Cervical Dystonia
NCT06830642· Phase 2· Motric Bio· Source
Completed
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
NCT06665308· Sanofi· Source
Withdrawn
Imaging of the Esophagus Using a SECM Capsule
NCT03546660· Massachusetts General Hospital· Source
Terminated
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257· Phase 2· Rachel G. Greenberg, MD, MB, MHS· Source
Completed
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
NCT06262113· Massachusetts General Hospital· Source
Recruiting
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398· Phase 3· Intra-Cellular Therapies, Inc.· Source
Completed
Investigating the Relationship Between Glycemia and Sleep in Adults With Cystic Fibrosis-Related Diabetes
NCT06700889· Massachusetts General Hospital· Source
Completed
Sapphire 3 CTO Study
NCT06358508· OrbusNeich· Source
Completed
Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
NCT06472869· Massachusetts General Hospital· Source
Terminated
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711· Phase 3· Mannkind Corporation· Source
Completed
PACE CF, a 3-session Mind-body Pain Management Program for Adults With Cystic Fibrosis
NCT06606457· Massachusetts General Hospital· Source
Completed
A Phase 2b Study of Zagociguat in Patients With MELAS
NCT06402123· Phase 2· Tisento Therapeutics· Source
Recruiting
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608· Kardion Inc· Source
Completed
CHW Intervention to Improve Nutrition Security of Patients With Hypertension
NCT06358417· Massachusetts General Hospital· Source
Withdrawn
Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)
NCT04594616· Massachusetts General Hospital· Source
Completed
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342· Phase 2· Reveal Pharmaceuticals Inc.· Source
Completed
RECOVER-SLEEP: Platform Protocol
NCT06404086· Phase 2· Duke University· Source
Completed
RECOVER-ENERGIZE Platform Protocol
NCT06404047· Duke University· Source
Completed
Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy
NCT06387186· Phase 1· Elizabeth Anne Thiele· Source
Withdrawn
Immunomodulatory Effects of PCSK9 Inhibition
NCT05720156· Massachusetts General Hospital· Source
Withdrawn
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415· Phase 1· Hutchmed· Source
Completed
Supporting Our Caregivers In ADRD Learning (SOCIAL)
NCT06276023· Massachusetts General Hospital· Source
Completed
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
NCT06273124· Tandem Diabetes Care, Inc.· Source
Completed
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
NCT06208124· Phase 1/2· Immuneering Corporation· Source
Completed
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
NCT06265532· Phase 1· Hal Chapman· Source
Completed
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
NCT05995899· Phase 4· Kyle Staller, MD, MPH· Source
Completed
The T1D Parent Check-In: A Preventative Intervention
NCT06160934· Massachusetts General Hospital· Source
Completed
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
NCT06004167· Massachusetts General Hospital· Source
Completed
Mobile App Psychological Interventions for Family Dementia Caregivers
NCT05253443· Massachusetts General Hospital· Source
Terminated
PRO1107 in Patients With Advanced Solid Tumors
NCT06171789· Phase 1/2· Genmab· Source
Completed
Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial
NCT06089135· Baim Institute for Clinical Research· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Completed
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
NCT06234488· Medical College of Wisconsin· Source
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429· Cook Research Incorporated· Source
Completed
Esophageal Cancer Multimodal Prehabilitation Study
NCT06027515· Massachusetts General Hospital· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566· Phase 3· Sanofi· Source

Showing 50 of 414.

Registry name variants (89)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Massachusetts General Hospital
Boston, Massachusetts 02214
1,143 trials
Massachusetts General Hospital
Charlestown, Massachusetts 02129
26 trials
Massachusetts General Hospital - Boston
Boston, Massachusetts 02114
4 trials
Massachusetts General Hospital (Data Collection Only)
Boston, Massachusetts 02114
4 trials
Massachusetts General Hospital (Site 0003)
Boston, Massachusetts 02114
4 trials
Mass General
Boston, Massachusetts 02114
4 trials
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
Boston, Massachusetts 02114
3 trials
- NCT07733765A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- NCT04006457Long-Term PF-06651600 for the Treatment of Alopecia Areata
- NCT03422822Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Massachusetts General Hospital
Lexington, Massachusetts 02421
2 trials
- NCT06042257Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
- NCT04278404Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  Contact: Chi Hornik
Massachusetts General Hospital
Somerville, Massachusetts 02144
2 trials
- NCT07102797ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence
  Contact: Rachel Whooten
- NCT05358353A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
Massachusetts General Hospital/Dana Farber Cancer Institute
Boston, Massachusetts 02114
2 trials
- NCT04981119Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
  Contact: Clinical Trials
- NCT03435796Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
  Contact: Jeremy Abramson, Site 01012
Massachusetts General Hospital-Hospital
Boston, Massachusetts 02114
2 trials
- NCT07575269Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
  Contact: Peter Fox
- NCT05443594A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Massachusetts General Hospital - Neurology
Boston, Massachusetts 02114
2 trials
- NCT06914128A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Massachusetts General Hospital, Neuromuscular Diagnostic Center
Boston, Massachusetts 02114
2 trials
- NCT07226830Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
  Contact: Amanda Guidon, MD MPH
- NCT07224386Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
  Contact: Amanda Guidon
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
Boston, Massachusetts 02114
2 trials
- NCT05306873Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
- NCT05000216COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Massachusetts General Hospital Site Number : 8400001
Boston, Massachusetts 02114
2 trials
- NCT06665308Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
- NCT05237284Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Massachusetts General Hospital Site Number : 8400002
Boston, Massachusetts 02114
2 trials
- NCT04659603Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
- NCT03284957Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Massachusetts General Hospital (The General Hospital Corp.)
Boston, Massachusetts 02114
2 trials
- NCT07277309Promoting Recovery After Brain Injury Using Focused Ultrasound
  Contact: Michael Young, MD, MPhil
- NCT06939348Ultrasound Stimulation for Patients in a Disorder of Consciousness
  Contact: Michael Young, MD
Neuromuscular Diagnostic Center - Massachusetts General Hospital
Boston, Massachusetts 02114
2 trials
- NCT06450886Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
- NCT05721573A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Boston Children's/Joslin Diabetes Center/Massachusetts General Hospital
Boston, Massachusetts 02215
1 trial
- NCT06525259DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
  Contact: Jackson Tu
Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
Boston, Massachusetts 02114
1 trial
- NCT05767593Clinical Validation of Samsung Smartwatch
Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital
Boston, Massachusetts 02114
1 trial
- NCT01075672Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Dana-Farber/Massachusetts General Hospital, Inc
Boston, Massachusetts 02215
1 trial
- NCT07300150A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  Contact: Leon Pappas
Diabetes Research Center, Massachusetts General Hospital
Boston, Massachusetts 02114
1 trial
- NCT07688070Verapamil Effect in Cystic Fibrosis-related Dysglycemia
  Contact: Melissa Putman
Disparities Research Unit, Massachusetts General Hospital
Boston, Massachusetts 02114
1 trial
- NCT07091032Building Connections
  Contact: Margarita Alegria, Ph.D.
Laboratory for Translational Neurorecovery, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital
Boston, Massachusetts 02114
1 trial
- NCT06998485Substrates for Post-Stroke Arm Rehabilitation
  Contact: Caroline Lambert
Massachusetts General Hospital
Waltham, Massachusetts 02451
1 trial
- NCT04844606A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  Contact: Jess Kaplan (principal investigator)
Massachusetts General Hospital - ALS Site
Boston, Massachusetts 02129
1 trial
- NCT05189106Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
Massachusetts General Hospital - Cardiology
Boston, Massachusetts 02114
1 trial
- NCT07625215A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
Massachusetts General Hospital_Cary
Boston, Massachusetts 02114
1 trial
- NCT05726227A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Massachusetts General Hospital - Center for Celiac Research and Treatment
Boston, Massachusetts 02114
1 trial
- NCT04671433Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Massachusetts General Hospital, Co-Enrolling through ABC-DS Only
Boston, Massachusetts 02114
1 trial
- NCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
  Contact: Herminia Herminia Diana Rosas (principal investigator)
Massachusetts General Hospital - Crohn's and Colitis Center
Boston, Massachusetts 02114
1 trial
- NCT02914535Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164257
Boston, Massachusetts 02114
1 trial
- NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Massachusetts General Hospital - Dana Farber
Boston, Massachusetts 02114
1 trial
- NCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Massachusetts General Hospital (Data Collection and Specimen Analysis)
Boston, Massachusetts 02114
1 trial
- NCT03824483Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Massachusetts General Hospital, Healey & AMG Center for ALS
Boston, Massachusetts 02114
1 trial
- NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  Contact: Lucy Lee
Massachusetts General Hospital /ID# 141552
Boston, Massachusetts 02114
1 trial
- NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
Massachusetts General Hospital /ID# 153990
Boston, Massachusetts 02114
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Massachusetts General Hospital /ID# 155267
Boston, Massachusetts 02114
1 trial
- NCT02988960A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Massachusetts General Hospital /ID# 165678
Boston, Massachusetts 02114
1 trial
- NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
Massachusetts General Hospital /ID# 200474
Boston, Massachusetts 02114
1 trial
- NCT03569293Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Massachusetts General Hospital /ID# 200752
Boston, Massachusetts 02114
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Massachusetts General Hospital /ID# 203215
Boston, Massachusetts 02114
1 trial
- NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Massachusetts General Hospital /ID# 207549
Boston, Massachusetts 02114
1 trial
- NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
Massachusetts General Hospital /ID# 217307
Boston, Massachusetts 02114
1 trial
- NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Massachusetts General Hospital /ID# 221559
Boston, Massachusetts 02114
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Massachusetts General Hospital /Id# 224335
Boston, Massachusetts 02114
1 trial
- NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Massachusetts General Hospital /ID# 225068
Boston, Massachusetts 02114
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Massachusetts General Hospital /ID# 245233
Boston, Massachusetts 02114
1 trial
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Massachusetts General Hospital /ID# 245239
Boston, Massachusetts 02114
1 trial
- NCT05451810A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Massachusetts General Hospital /ID# 250142
Boston, Massachusetts 02114
1 trial
- NCT05782907Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Massachusetts General Hospital /Id# 259817
Boston, Massachusetts 02114
1 trial
- NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Massachusetts General Hospital /Id# 261051
Boston, Massachusetts 02114
1 trial
- NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Massachusetts General Hospital /ID# 261093
Boston, Massachusetts 02114
1 trial
- NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Massachusetts General Hospital /ID# 268879
Boston, Massachusetts 02114
1 trial
- NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Massachusetts General Hospital /ID# 273608
Boston, Massachusetts 02114
1 trial
- NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Massachusetts General Hospital /ID# 278119
Boston, Massachusetts 02114
1 trial
- NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Massachusetts General Hospital - Main Campus
Boston, Massachusetts 02114
1 trial
- NCT07629960A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  Contact: Blueprint Medicines
Massachusetts General Hospital (MG)
Boston, Massachusetts 02114
1 trial
- NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  Contact: Erasca Clinical Team Team
Massachusetts General Hospital - Pediatric Epilepsy Program
Boston, Massachusetts 02114
1 trial
- NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
Massachusetts General Hospital - Pulmonary Associates
Boston, Massachusetts 02114
1 trial
- NCT06097260Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Massachusetts General Hospital: Rheumatology
Boston, Massachusetts 02114
1 trial
- NCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
  Contact: Sheila Arvikar, MD
Massachusetts General Hospital (Site 0018)
Boston, Massachusetts 02114
1 trial
- NCT05458297A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Massachusetts General Hospital (Site 0038)
Boston, Massachusetts 02114
1 trial
- NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Massachusetts General Hospital (Site 0062)
Boston, Massachusetts 02114
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Massachusetts General Hospital (Site 0094)
Boston, Massachusetts 02114
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Massachusetts General Hospital (Site 0111)
Boston, Massachusetts 02114
1 trial
- NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  Contact: Study Coordinator
Massachusetts General Hospital (Site 0126)
Boston, Massachusetts 02114
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Massachusetts General Hospital (Site #0131)
Boston, Massachusetts 02114
1 trial
- NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
  Contact: Principal Investigator
Massachusetts General Hospital (Site 0136)
Boston, Massachusetts 02114
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
Massachusetts General Hospital (Site 0603)
Boston, Massachusetts 02114
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Massachusetts General Hospital (Site 1035)
Boston, Massachusetts 02114
1 trial
- NCT04624243Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Massachusetts General Hospital (Site 1558)
Boston, Massachusetts 02114
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Massachusetts General Hospital (Site 1622)
Boston, Massachusetts 02114
1 trial
- NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Massachusetts General Hospital (Site 1927)
Boston, Massachusetts 02114
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Massachusetts General Hospital (Site 3571)
Boston, Massachusetts 02114
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Massachusetts General Hospital (Site 4003)
Boston, Massachusetts 02114
1 trial
- NCT05270668Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Massachusetts General Hospital Site Number: 8400004
Boston, Massachusetts 02114
1 trial
- NCT07007962Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Massachusetts General Hospital- Site Number : 8400009
Boston, Massachusetts 02114
1 trial
- NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
~Massachusetts General Hospital Site Number : 8400011
Boston, Massachusetts 02114
1 trial
- NCT03754790Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
~Massachusetts General Hospital- Site Number : 8400017
Boston, Massachusetts 02114
1 trial
- NCT05911763A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Massachusetts General Hospital Site Number : 840002
Boston, Massachusetts 02114
1 trial
- NCT02201108Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Massachusetts General Hospital- Site Number : 8401192
Boston, Massachusetts 02114
1 trial
- NCT06130566A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Massachusetts General Hospital Site Number : 84038
Boston, Massachusetts 02114
1 trial
- NCT04562766Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Massachusetts General Hospital (Surgical)
Boston, Massachusetts 02114
1 trial
- NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Massachusetts General Hospital, Translational and Clinical Research Center
Boston, Massachusetts 02114
1 trial
- NCT04798079Systems Biology of Early Atopy
Massachusetts General Hospital: Transplantation (Site #: 71107)
Boston, Massachusetts 02114
1 trial
- NCT06056102CAR-T Cell Therapy for Desensitization in Kidney Transplantation
  Contact: Sydney Guthrie-Baker
Massachusetts General Hospital, University of California San Francisco, University of Utah
Boston, Massachusetts 02114
1 trial
- NCT05150093Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
  Contact: Kristina Simonyan, MD, PhD
Mass General / North Shore Can
Boston, Massachusetts 02114
1 trial
- NCT03505320A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Conditions

Diseases this institution publishes on or runs trials for.

Alzheimer disease618 works · 25 trials
Stroke524 works · 41 trials
HIV316 works · 21 trials
Heart failure288 works · 44 trials
Obesity287 works · 28 trials
Lung cancer253 works · 147 trials
Type 2 diabetes188 works · 18 trials
Atrial fibrillation180 works · 25 trials
Melanoma180 works · 68 trials
Coronary artery disease156 works · 38 trials
Colorectal cancer136 works · 85 trials
Prostate cancer135 works · 42 trials
Depression118 works · 20 trials
Epilepsy114 works · 21 trials
Parkinson disease113 works · 23 trials
Schizophrenia111 works · 7 trials
Liver and biliary tract cancer107 works · 40 trials
Pancreatic cancer83 works · 65 trials
Osteoarthritis83 works · 9 trials
Chronic kidney disease80 works · 11 trials
Sarcoma77 works · 34 trials
Bipolar disorder77 works · 10 trials
Multiple sclerosis73 works · 16 trials
Asthma71 works · 6 trials
ALS (motor neurone disease)70 works · 27 trials
Ovarian cancer67 works · 64 trials
Autism63 works · 9 trials
Glioblastoma63 works · 26 trials
Tuberculosis59 works · 0 trials
Multiple myeloma58 works · 45 trials

Institution data: ROR 002pd6e78 (CC0-1.0)Updated 12 Nov 2026

Report an error